title: Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
abstract: Gastric cancer is one of the leading causes of cancer related deaths worldwide. Regional differences in gastric cancer are evident between Asian and Western societies with respect to etiology, prevalence, clinicopathologic features as well as treatment pattern of the disease. For patients with advanced gastric cancer (AGC), chemotherapy has been found to improve survival and quality of life compared to best supportive care alone. But contrast to other tumors such as colon or pancreatic cancer, there are regional differences in outcome in gastric cancer. Various geographic/ethnic, biology and treatment strategies may contribute to these differences. In the first line setting, cisplatin and fluoropyrimidine based therapies remain the backbone of treatment for advanced gastric cancer in Asian and Western patients, although there is preference for S1 in Asia and 5FU in the West. A third agent may be added in patients with good performance status. Recent trials from Asia and Europe demonstrate an advantage for second line chemotherapy. Irinotecan and taxanes are the most commonly used agents. The introduction of trastuzumab into the frontline therapy of AGC has ushered the age of targeted therapy and personalized medicine in this disease. In this article, we will review the various first and second line chemotherapy regimens in AGC, taking into account regional differences including potential biomarkers.
authors.affiliation: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive FOB-2, Tampa, FL 33612, USA. Electronic address: Richard.Kim@moffitt.org.
authors.forename: Richard
authors.initials: R
authors.lastname: Kim
authors.forename: Ann
authors.initials: A
authors.lastname: Tan
authors.forename: Minsig
authors.initials: M
authors.lastname: Choi
authors.forename: Bassel F
authors.initials: BF
authors.lastname: El-Rayes
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001208:Asia; D015415:Biomarkers; D019049:Developed Countries; D062306:Geography, Medical; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D016879:Salvage Therapy; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers
keywords: Advanced gastric cancer; Biomarkers; Chemotherapy; Regional differences